Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients

Clin Chem Lab Med. 2021 Jun 14;59(11):e413-e415. doi: 10.1515/cclm-2021-0561. Print 2021 Oct 26.

Authors

Giuseppe Lippi¹, Brandon M Henry², Emmanuel J Favaloro³

Affiliations

¹ Section of Clinical Biochemistry, University of Verona, Verona, Italy.
² Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
³ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia.

PMID: 34116589
DOI: 10.1515/cclm-2021-0561

No abstract available

Keywords: COVID-19; coronavirus; soluble urokinase plasminogen activator receptor; suPAR.

MeSH terms

Adult
Aged
Aged, 80 and over
Biomarkers / blood
Biomarkers / metabolism*
COVID-19 / diagnosis
COVID-19 / metabolism*
Coronavirus Infections / complications
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Oxidative Stress
Prospective Studies
Receptors, Cell Surface
Receptors, Urokinase Plasminogen Activator / blood
Receptors, Urokinase Plasminogen Activator / metabolism*
SARS-CoV-2 / metabolism*
Signal Transduction

Substances

Biomarkers
PLAUR protein, human
Receptors, Cell Surface
Receptors, Urokinase Plasminogen Activator